- Home
- MYFW vs IPHA Comparison
MYFW vs IPHA Comparison
Compare MYFW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYFW
- IPHA
- Stock Information
- Founded
- MYFW 2002
- IPHA 1999
- Country
- MYFW United States
- IPHA France
- Employees
- MYFW N/A
- IPHA N/A
- Industry
- MYFW Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MYFW Finance
- IPHA Health Care
- Exchange
- MYFW Nasdaq
- IPHA Nasdaq
- Market Cap
- MYFW 169.4M
- IPHA 191.0M
- IPO Year
- MYFW 2018
- IPHA 2019
- Fundamental
- Price
- MYFW $19.46
- IPHA $2.28
- Analyst Decision
- MYFW Buy
- IPHA Strong Buy
- Analyst Count
- MYFW 3
- IPHA 1
- Target Price
- MYFW $20.67
- IPHA $11.50
- AVG Volume (30 Days)
- MYFW 19.4K
- IPHA 6.3K
- Earning Date
- MYFW 10-17-2024
- IPHA 09-12-2024
- Dividend Yield
- MYFW N/A
- IPHA N/A
- EPS Growth
- MYFW N/A
- IPHA N/A
- EPS
- MYFW 0.36
- IPHA N/A
- Revenue
- MYFW $80,146,000.00
- IPHA $36,202,722.00
- Revenue This Year
- MYFW N/A
- IPHA N/A
- Revenue Next Year
- MYFW $11.04
- IPHA $105.84
- P/E Ratio
- MYFW $54.46
- IPHA N/A
- Revenue Growth
- MYFW N/A
- IPHA N/A
- 52 Week Low
- MYFW $12.84
- IPHA $1.81
- 52 Week High
- MYFW $21.15
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- MYFW 58.97
- IPHA 50.55
- Support Level
- MYFW $18.70
- IPHA $2.27
- Resistance Level
- MYFW $19.53
- IPHA $2.41
- Average True Range (ATR)
- MYFW 0.65
- IPHA 0.11
- MACD
- MYFW 0.11
- IPHA -0.00
- Stochastic Oscillator
- MYFW 81.78
- IPHA 52.94
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.